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Abstract
Understanding of the molecular mechanisms in the opioid systems in chronic pain should produce new, more
effective methods of the pharmacotherapy of pain. Pharmacological suppression of glial activation in combi-
nation with morphine, methadone, fentanyl and buprenorphine may be an important aspect of pain therapy.
Long-term use of the classical opioid analgesics in patients with chronic pain processes results in tolerance,
and the search of new treatment strategies based on the recognised mechanisms of pain is an important
clinical and scientific issue.
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The opioid systems
Opioid peptides
Opioid peptides are derived from three precur-
sors: proopiomelanocortin (POMC), proenkephalin
and prodynorphin. Proopiomelanocortin is the pre-
cursor of the opioid peptides a-, b- and g-endorphin
and of the non-opioid peptides ACTH, a- and b-
MSH, CLIP and b-LPH. Of these peptides, the best
investigated one is b-endorphin, which plays an im-
portant role in stress, transmission of nociceptive
stimuli, hormonal regulation and in the regulation
of immune function. Proenkephalin is the precursor
of Leu- and Met-enkephalin, Met-enkephalin-Arg6-
Gly7-Leu8, Met-enkephalin-Arg6-Phe7, BAM, peptide
E and peptide F. These peptides are involved in the
mechanisms of nociception, motivational process-
es, modulation of the extrapyramidal system and
the regulation of convulsive states. Prodynorphin
gives rise to dynorphin A, dynorphin B (rimorphin)
and a- and b-neoendorphin. There is evidence that
certain peptides derived from prodynorphin exert
non-opioid effects in addition to opioid effects and
for this reason are classified as non-opioid neuropep-
tides [1–8]. In 1997 Zadina et al. discovered new
endogenous peptides with a very high affinity and
selectivity to the MOP opioid receptor. Due to their
selective effect on the receptor through which mor-
phine exerts its actions they have been called endo-
morphins [9]. While nothing is known about their
precursors and genes, their location in the brain-
stem, spinal cord and nerve ganglia as well as their
coexistence with the MOP opioid receptor suggest
an important role in nociception [10]. They current-
ly serve as instrumental substances in basic research
[11, 12].
The opioid peptide precursors discovered so far
are encoded by three genes. These genes share many
structural similarities, which might indicate a shared
evolutional origin. The similarities also involve the
length of peptide chains of these precursors, as proo-
piomelanocortin, proenkephalin and prodynorphin
contain 265, 263 and 256 amino acids, respectively
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[13]. Peptides originating from these precursors have
heterogenous structures and bind to different opio-
id receptors, but contain thyrosine as the N-termi-
nal amino acid (Table 1).
Opioid receptors
Opioid peptides act through specific receptors.
Three opioid receptors are distinguished: m, d and
k, currently referred to as MOP (m-opioid peptide),
DOP and KOP. Endogenous MOP receptor ligands
include endomorphins, POMC-derived peptides and
enkephalins. Endogenous DOP receptor ligands are
enkephalins and endogenous KOP receptor ligands
include prodynorphin-derived peptides [14]. The iso-
lated receptor proteins have vary with respect to
molecular mass (MOP: 65 kDa, DOP: 53 kDa, KOP:
55 and 35 kDa) [15–19]. All the three opioid recep-
tors have been cloned (DOP [16, 17], followed by
KOP [19] and most recently MOP [18]). The opioid
receptors consist of seven hydrophobic transmem-
brane domains, three intracellular loops and the C-
terminus located inside the cell, and three extracel-
lular loops and the N-terminus located outside the
cell. The opioid receptors cloned in rodents are ap-
proximately 65% homologous in terms of the ami-
no acid sequence. The greatest similarity is found in
the transmembrane domains and the intracellular
loops and the greatest differences are found in the
N- and C-termini and the extracellular loops. The
opioid receptors in humans show a considerable
similarity in amino acid sequence and in the selec-
tivity of ligands compared to the receptors found in
rodents [20–22].
Receptor cloning has made it possible to describe
their molecular structure in detail, leading to signifi-
cant progress in functional research. Opioid recep-
tors are G-protein-coupled receptors. The opioid
agonists of the MOP, DOP and KOP receptors inhibit
adenylate cyclase via activation of Gi and Go proteins
[8, 16, 19, 23, 24]. Opioids not only affect secondary
messengers but also ion-mediated signal transmis-
sion inside cells. Opioids are believed to suppress the
excitability of nerve cells by means of two mecha-
nisms: inhibition of Ca2+-mediated signal transmis-
sion and augmentation of K+-mediated signal trans-
mission [25]. It is difficult to understand the actions
of opioids derived from proopiomelanocortin, proen-
kephalin and prodynorphin as they lack specific ef-
fects on any single type of opioid receptors, MOP,
DOP or KOP. The only exception are endomorphins,
which are characterised by a high affinity (endomor-
phin-1, Ki = 360 pM; endomorphin-2; Ki = 690 pM)
and a high selectivity for the MOP opioid receptor [9,
10]. Studies of opioid systems principally utilise syn-
thetic analogues, most commonly non-peptide pep-
tidase-resistant substances with high selectivity for
specific types and often subtypes of receptors. The
endogenous opioids endomorphin-1 and endomor-
phin-2 activate G protein similarly to the synthetic
agonist DAMGO [26]. Morphine, DAMGO and endo-
morphin-1 activate Gi1a/Gi2a, Goa and Gi3a proteins in a
similar manner and Gqa/G11a and Gsa in a different
manner, which may be the reason for the differences
observed in the internalization of the MOP opioid
receptor seen between morphine and these peptides
[27]. It seems interesting that excision of 33 amino
acid at the C-terminus does not affect the binding of
DAMGO, morphine and naloxone to the MOP opioid
receptor but deprives the receptor of the ability to
interact with the system inhibiting the formation of
cAMP by DAMGO but not by morphine. This suggests
distinct differences in the possibilities to regulate the
level of secondary messengers between peptide ago-
nists, such as DAMGO, and alkaloid agonists, such as
morphine [15]. Additionally it has been demonstrat-
ed in the recent years that morphine does not cause
internalization of the MOP opioid receptor (shifting
into the cells) and its return to the cell membrane,
while DAMGO and endomorphins do [27]. This differ-
ence is currently viewed as the reason for changes in
the efficacy of morphine, such as tolerance or the
reduction in effectiveness in neuropathic pain.
Radioligand binding assays have demonstrated
the presence of two MOP receptor subtypes in the
Table 1. Selected endogenous opioid peptides, their precursors and structures
Precursor Peptide Structure
POMC  b-endorphin(1–31) H-Tyr-Gly-Gly-Phe-Met-Tyr-Ser-Glu-Lys-Ser-
Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-
Ile-Ile-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln-OH
PENK Met-enkephalin H-Tyr-Gly-Gly-Phe-Met-OH
PDYN Dynorphin A(1–17) H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-
Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-OH
Unknown Endomorphin-1 H-Tyr-Pro-Trp-Phe-NH2
Unknown Endomorphin-2 H-Tyr-Pro-Phe-Phe-NH2
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rat brain, subtype 1 and subtype 2, differing in terms
of affinity for their selective antagonists, naloxona-
zine and naloxazone, respectively. The presence of
MOP receptor subtypes is confirmed by studies us-
ing antisense oligonucleotide which suggest that
MOP receptor subtype 1, which is involved in the
antinociceptive action of morphine at the higher
levels of the nervous system, contains a polypep-
tide sequence encoded by exons 1 and 4, while the
MOP receptor subtype 2, which is involved in the
antinociceptive action of morphine at the level of
the spinal cord and in intestinal motility, contains a
polypeptide sequence encoded by exon 4 only. The
presence of a third MOP receptor subtype is also
postulated. The receptor would be responsible for
the analgesic effects of morphine glucuronate rath-
er than pure morphine. The amino acid sequence of
this receptor is believed to be encoded by exons 2
and 3 rather than exons 1 and 4 [28]. Subtype 1
receptors show high affinity for morphine and cer-
tain enkephalins as well as synthetic DOP receptor
ligands, such as DADLE (D-Ala2-D-Leu5-enkephalin)
and DSLET (Tyr-D-Ser2-Gly-Phe-Leu5-Thr-enkephalin).
Subtype 2 receptors, on the other hand, show low
affinity for the classic MOP receptor agonists, such
as morphine and DAMGO (D-Ala2-MePhe4-Gly-(ol)5-
enkephalin) [29, 30].
Numerous studies also suggest the existence of
DOP receptor subtypes, whose agonists include DP-
DPE and deltorphin I in the case of subtype 1 and
deltorphin II in the case of subtype 2. Antagonists of
subtype 1 include 7-benzylidenenaltrexone (BNTX)
and D-Ala2,Leu5,Cys6-enkephalin (DALCE), while those
of subtype 2 are naltriben (NTB) and naltrindole 5'-
isothiocyanate (NTII) (Table 2). The existence of DOP
receptor subtypes is further supported by the fact
that the agonists DPDPE and deltorphin II do not
exhibit cross-tolerance. Also the selective DOP antag-
onists DALCE and NTII differently antagonise analge-
sic effects of DPDPE and deltorphin II [31, 32]. Both
DOP receptor subtypes may also be activated by the
endogenous opioids enkephalin and b-endorphin.
Studies using antisense oligodeoxynucleotides sug-
gest that the cloned DOP receptor corresponds with
subtype 2, as administration of anti-DOP-receptor
antisense oligodeoxynucleotide into the lateral ven-
tricle of the brain suppressed analgesic effects of
deltorphin II but not those of DPDPE [28, 33].
Ligand binding studies also suggest the exist-
ence of KOP receptor subtypes. It is believed that
specific agonists of subtype 1 include acrylaceta-
mide compounds, U69,593 and U50,488H, those
of subtype 2 include bremazocine and ethylketocy-
clazocine and those of subtype 3 include the nalox-
one derivative NalBzoH (Table 2). There are also cer-
tain suggestions indicating the existence of sub-
type 4 [28].
POMC- and proenkephalin-derived endogenous
opioid peptides show higher affinity for the MOP
and DOP receptors than for the KOP receptor, while
prodynorphin-derived peptides principally bind with
the KOP receptor [34]. It should be emphasised that
none of the known endogenous opioid peptides,
with the exception of endomorphins, is not selec-
tive for just one opioid receptor type. Defining the
roles of specific opioid receptor subtypes is of par-
ticular importance, as it is more effective to use
drugs that exert their actions through various opio-
id receptors, such as morphine (an agonist of the
MOP and DOP), methadone (an agonist of the MOP,
DOP and KOP receptors), fentanyl (a potent agonist
of the MOP receptor and a weak agonist of the DOK
and KOP receptors), buprenorphine (a partial ago-
nist of the MOP, DOK and KOP receptors and an
agonist of the NOP [nociception peptide] receptor).
The use of various types and even subtypes of opio-
id receptors in a rotational manner for the manage-
ment of chronic pain may enable long-term and
effective treatment with opioids.
Antinociceptive effects of opioids
Neuromodulation in nociceptive processes in-
volves modulation of both the efferent and the af-
ferent transmission of nociceptive stimuli. Peripher-
al neurons transmit nociceptive stimuli from noci-
ceptors in the peripheral tissues to the dorsal cor-
nua of the spinal cord, from where the impulses are
conveyed to the hypothalamus directly through the
spinothalamic tracts to the intralaminar nuclei or
indirectly through the spinoreticular tracts, reticu-
lar nuclei and the periaqueductal grey matter to the
ventroposterior nuclei of the thalamus, from where
thalamic cells project axons to the cerebral cortex
[35, 36]. The existence of inhibitory descending path-
ways called antinociceptive pathways is supported
by the potent analgesia elicited by administration
of opioids into the subarachnoid space. Also the
stimulation of efferent fibres leaving the periaque-
ductal grey substance and reaching the posterior
cornua of the spinal cord leads to potent analgesic
effects [35, 36].
Immunocytochemical assays and in situ hybridi-
sation have confirmed that both opioid peptides
and mRNA encoding their precursors are found at
all the levels of neuronal pathways. POMC-contain-
ing neurons are found in the arcuate nucleus of the
thalamus, periaqueductal grey matter, thalamic
nuclei, raphe nuclei, limbic system and in the nucle-
Advances in Palliative Medicine 2008, vol. 7, no. 4
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Table 2. Ligands of MOP, DOP and KOP opioid receptors and of the NOP receptor
Type of the receptor
MOP DOP KOP NOP
Endogenous agonists
Endomorphin-1 X
Endomorphin-2 X
 b-endorphin X X
Met-enkephalin x X x
Leu-enkephalin x X x
Dynorphin x x X
Nociceptin X
Synthetic agonists
DAMGO X
DPDPE X
[D-Ala2]deltorphin I X
[D-Ala2]deltorphin II X
SNC80 X
ICI 199 441 X
ICI 174 864 X
PD 111 7302 X
U50 488H X
Bremazocine X
NalBzoH X
RO64-6198 X
RO65-6570 X
Drugs used in clinical practice
Morphine X X
Pethidine X
Tramadol X x x
Oxycodone X X
Codeine X
Pentazocine X
Fentanyl X x x
Methadone X X X
Buprenorphine x x x X
Antagonists
Naloxone X X X
Cyprodime X
CTOP X
Naloxonazine X
Naloxazone X
BNTX X
NTII X
NTB X
norBNI X
GNTI X
J-113397 X
JTC-801 X
CompB X
NPhe [N-Phe1]-NC(1–13)NH2 X
PheY [Phe1 Y(CH2-NH)Gly2]NC(1–13)NH2 X
Affinity for the receptor type: X — potent; x — weak
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us of the solitary tract, from where they project to
the spinal cord. Proenkephalin- and prodynorphin-
containing neurons are widespread throughout the
structures of the central nervous system. Large quan-
tities of these substances are found in the periaque-
ductal grey substance, thalamus, raphe nuclei and
in the layers of the dorsal cornua of the spinal cord.
Smaller quantities are found in the cerebral cortex.
Their co-localisation is common [37].
The involvement of opioid systems in the trans-
mission of nociceptive stimuli supports the fact that
electric stimulation of neurons projecting from the
periaqueductal grey substance, raphe nuclei and the
reticular nuclei to the spinal cord results in analge-
sia, which is associated with the secretion of opio-
ids in these structures [35]. Additionally, injury to
the arcuate nucleus of the hypothalamus attenu-
ates the analgesic effects caused by electrical stim-
ulation of the periaqueductal grey substance, where
b-endorphin nerve endings are found [35]. b-Endor-
phin and the exogenous MOP receptor agonists,
when administered into the lateral ventricle of the
brain and supraspinally in rodents, show analgesic
action [38, 39].
According to the anatomical data, all the three
types of opioid receptors may mediate the analge-
sic effects of opioids. In the descending pathways,
all the opioid receptor types are found in the peri-
aqueductal grey substance, reticular nuclei of the
pons (the gigantocellular and the intermediate re-
ticular nuclei) with a predominance of MOP and
KOP receptors in the raphe nuclei (the central raphe
nuclei and the nucleus raphe magnus). In the as-
cending neuronal nociceptive pathways, in the gan-
glia of the dorsal radices, spinal cord and the spinal
trigeminal nucleus, MOP, KOP and DOP receptors
are present. In the thalamus, MOP and KOP recep-
tors predominate with a much lower number of
DOP receptors. The distribution of MOP, DOP and
KOP receptors as well as their mRNAs in the spinal
cord and the ganglia suggests a very important role
in the modulation of nociceptive information, as
reported by many authors [40–42].
In the lumbar region of the spinal cord, MOP
mRNA is localised principally in layers I–II, which is a
location of particular importance for nociceptive
processes due to the termination of the primary C
and Ad fibres and Met-enkephalin-containing fibres.
This suggests a very important contribution to the
modulation of nociceptive information conveyed by
postsynaptic receptors localised on primary ascend-
ing fibres. MOP mRNA is also found in layers III and
IV and in the ventral part of the lumbar region of
the spinal cord in layers VII and VIII, which suggests
an involvement in the nociceptive impulse trans-
mission through the spinothalamic and spinoretic-
ular tracts. Layer IX demonstrates a very poor ex-
pression of MOP mRNA, while some expression of
MOP mRNA is observed in layer X, which suggests
that these receptors affect the nociceptive informa-
tion conveyed to the lateral reticular nucleus, gi-
gantocellular reticular nucleus and the lateral para-
gigantocellular reticular nucleus. The expression of
DOP mRNA in the lumbar region of the spinal cord
is relatively high with layer IX showing the highest
expression, which supports the presence of DOP
mRNA in motor neurons. The greatest concentra-
tion of cells which express KOP mRNA is seen in
layers I and II of the lumbar region of the spinal
cord. These layers also contain dynorphin-contain-
ing fibres [3, 43], which suggests that the KOP opi-
oid receptor, similarly to the MOP receptor, plays a
very important role in the modulation of nocicep-
tive information through postsynaptic receptors on
the primary ascending fibres.
In the structures of the higher levels of the cen-
tral nervous system there is a strong correlation
between opioid receptor mRNA and ligand binding
by these receptors. At the level of the spinal cord,
on the other hand, in layers I–II, the MOP, DOP and
KOP receptor binding exceeds their mRNA levels,
which suggests presynaptic distribution of these
receptors on the endings of the primary ascending
fibres reaching the spinal cord from the ganglia of
the dorsal roots. On the other hand, the deeper
layers of the spinal cord demonstrate a strong cor-
relation between the opioid receptor mRNA and
ligand binding with postsynaptic receptors being
the most likely cause [41]. In the central nervous
system, large neurons principally express DOP re-
ceptors, while intermediate and small neurons main-
ly express KOP receptors. Intermediate and large
neurons also contain MOP mRNA. The coexistence
of MOP and DOP receptors and of MOP and KOP, but
not of DOP and KOP, is very likely. It is possible that
MOP and DOP receptors and MOP and KOP recep-
tors form receptor complexes which may be involved
differently in the transmission of nociceptive stimuli
[41]. One of the mechanisms of action of opioids
involves the inhibition of neurotransmitter secretion
by primary afferent fibres. In situ hybridisation has
demonstrated opioid receptor mRNA in the ganglia
of the dorsal roots [41], where bodies of the primary
fibre cells are found. In the ganglia, MOP mRNA ex-
pression is very high and is observed in approximate-
ly 55% of neurons, while DOP mRNA and KOP mRNA
expression amounts to 20% and approximately 18%,
respectively. Undoubtedly, the opioid receptors
Advances in Palliative Medicine 2008, vol. 7, no. 4
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present in these locations play a very important role
in nociceptive transmission [10].
The significance of the MOP opioid receptor in
nociceptive transmission has been confirmed by
studies in MOP knockout mice, which showed a
lack of analgesic effects following administration
of endomorphins (selective ligands of this receptor)
[44]. In inflammation caused by formalin weaker
effects of endomorphins than those of DAMGO and
morphine are observed, while in neuropathic pain
endomorphins act better than morphine [12]. Proen-
kephalin-derived peptides and their analogues also
trigger central antinociception. In the case of en-
dogenous peptides, this effect is brief because they
are readily cleaved by proteolytic enzymes. Their
analogues, on the other hand, are resistant to pro-
teolytic enzymes and show an antinociceptive ac-
tivity when administered into the ventricles and in-
trathecally [38, 39]. The involvement of prodynor-
phin-derived peptides in the mechanisms of nocice-
ption is unclear. There have been reports of the
absence of analgesic effects after these peptides
were administered into the lateral ventricle of the
brain [4] and of the elevation of the pain threshold
after intrathecal administration [6, 45]. The increased
spinal dynorphin levels observed in the neuropathic
pain models supports the notion that dynorphin
may play an important role in chronic pain [1, 3, 5,
43], especially since both dynorphin and the KOP
receptor in the spinal cord are mainly located in
structures associated with transmission of nocicep-
tive stimuli. Research has also shown that high dos-
es of intrathecal dynorphin damage the spinal cord
[46]. Studies investigating the effects of dynorphin
A1–17 on the intracellular Ca2+ concentration indicate
its dual modulation role. High levels of dynorphin
A1–17 have been shown to increase intracellular Ca2+
levels, which is associated with the activation of
both the NMDA and the KOP receptors, while low
levels of dynorphin A1–17 have been demonstrated
to suppress Ca2+-mediated signal transmission [47].
By increasing intracellular Ca2+ levels, dynorphin
seems to be capable of modulating the effects of
morphine, as confirmed by studies demonstrating
that the calcium antagonist nifedipine potentiates
antinociceptive effects and delays the development
of tolerance [48]. There is an increasing body of
evidence to support the involvement of NMDA re-
ceptors in the development and maintenance of
neuropathic pain. Our studies have shown that the
KOP receptor antagonist norbinaltorphimine (nor
BNI) and 5’-guanidinenonaltrindole (GNTI) increase
neuropathic pain. KOP blockade combined with si-
multaneous activation of endogenous dynorphin
results in dynorphin action on NMDA receptors, con-
tributing to the development of allodynia and hy-
peralgesia [3]. These studies prove that dynorphin
in neuropathic pain also exerts its effects through a
non-opioid mechanism leading to the development
of allodynia and hyperalgesia. Furthermore, intrathe-
cal MK-801 (a non-competitive NMDA antagonist)
or coadministration of antibodies to dynorphin A1–13
and morphine leads to complete antinociception
[3, 49, 50]. This means that the tonic activation of
the NMDA receptor following peripheral nerve dam-
age contributes to the reduced efficacy of morphine
in the neuropathic pain model [49, 50], which may
be of value in the search of a new target for analge-
sic treatments. Based on the experimental research
results, morphine is currently administered in com-
bination with ketimine in the clinical practice to
achieve an improved analgesia and less pronounced
adverse reactions [51].
The opioid drugs that act via the MOP receptor
continue to be the most effective analgesics avail-
able. Their efficacy in acute severe posttraumatic
and postoperative pain is unquestionable [52–54].
The use of opioids in relieving acute pain, including
postoperative pain, is common and uncontrover-
sial. Effective postoperative pain relief has been
proved to reduce the incidence of complications
and to shorten the duration of hospitalisation [52–
55]. According to the World Health Organisation
(WHO) recommendations, opioids are used in can-
cer pain, especially in the terminal phase [56]. In
patients with severe cancer pain potent opioids are
administered in combination with other drugs and
provide pain relief in 75–90% of the cases [54]. Of
the many potential benefits of combination analge-
sic pharmacotherapy the most important one is the
possibility of achieving additive or synergistic ef-
fects, thanks to which each of the drugs can be
given in lower doses and the incidence of adverse
reactions can be reduced [53]. It is common prac-
tice to co-administer two opioid drugs with similar
effects on opioid receptors, such as morphine and
fentanyl. In cancer patients, for instance, fentanyl
may be given via the transdermal route and imme-
diate-release morphine may be used for the treat-
ment of breakthrough pain [53]. The issue of com-
bining two opioid drugs is very interesting but its
complete understanding requires further studies [57,
58]. In animal experiments coadministration of mor-
phine and methadone with other MOP agonists (ox-
ycodone, oxymorphone, fentanyl, alfentanil or pethi-
dine) shows additive effects, which is most likely
due to the differences in MOP receptor subpopula-
tions and in the effects of the various agonists on
www.advpm.eu 191
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this receptor [58]. While morphine remains to be
the principal step 3 opioid analgesic in the WHO
analgesic ladder [56], given the insufficient analge-
sia and/or severe adverse reactions during oral mor-
phine treatment, there is an ongoing search of nov-
el therapies that would reduce adverse effects and
improve analgesia. One of the approaches, referred
to as opioid rotation or opioid switch, allows to
improve the analgesic effect and/or relieve severe
adverse reactions. Opioid rotation is used in the
clinical practice in cases of toxicity, insufficient pain
control and severe adverse reactions in the pres-
ence of good analgesic effect. Basic research has
provided evidence to support the existence of in-
complete cross-tolerance to individual opioids [30,
59], which may stem from hereditary differences in
the affinity and activation of specific receptors by
various opioids, individual differences in the phar-
macokinetics of specific opioids as well as tolerance
and interaction with other drugs [60, 61]. When
using opioid rotation in clinical practice one should
take into account dosing problems, especially the
difficulty predicting analgesic effects and adverse
reactions after the switch. One of the potent opioid
analgesics currently used in opioid rotation regi-
mens is methadone, as it shows analgesic effects in
patients who have become tolerant to other MOP
agonists [57, 58]. Another problem is neuropathic
pain due to its high severity, chronic nature and
refractoriness to treatment. Backonja et al. [62] rec-
ommend combination treatment with drugs with
different mechanisms of action, which may be ef-
fective in patients with neuropathic pain. The au-
thors recommend using antidepressants, anticon-
vulsive drugs and topical anaesthetic agents, such
as lidocaine and capsaicin, in addition to opioid
drugs [53].
Nociceptin (orphanin FQ) and the NOP
receptor
Attempts to clone opioid receptor subtypes have
led to the discovery of a new receptor called opioid
receptor-like (ORL1) by some researchers and or-
phan receptor by others, as no endogenous ligands
were known and opioids showed no affinity. The
currently accepted term is the NOP (nociceptin pep-
tide) receptor. In 1995 an endogenous peptide
ligand of this receptor was isolated termed nocice-
ptin/orphanin (N/OFQ) [63, 64]. The precursor of N/
OFQ is the pronociceptin gene, very similar to opio-
id precursors but showing particularly high struc-
tural similarity to prodynorphin. N/OFQ and dynor-
phin A are peptides with similar structures but the
former does not bind to opioid receptors due the
lack of N-terminal thyrosine (Table 3). The fact that
these peptides are found in various neurons and
show affinity for various receptors has considerable
neurophysiologic significance [65, 66].
Both N/OFQ and the NOP receptor are present in
many structures of the brain, spinal cord and gan-
glia [63, 67]. Co-localisation of N/OFQ, NOP recep-
tors and POMC-derived peptides has been shown in
the hypothalamus and the arcuate nucleus. It has
already been established that the NOP receptor is
also found on the enkephalinergic neurons of the
arcuate nucleus, hippocampus and the amygdala
and co-localisation of N/OFQ and dynorphin has
been confirmed in the substantia nigra and the arc-
uate nucleus [68]. Nerve fibres containing N/OFQ
and opioid peptides have been discovered in the
spinal cord [68]. In the ganglia of the dorsal roots,
N/OFQ is found only in the small neurons located in
the vicinity of neurons containing substance P and
CGRP. NOP receptors, on the other hand, are found
on 72% of the neurons containing substance P and
82% of the neurons containing CGRP, which sug-
gests that N/OFQ may presynaptically modulate
nociceptive transmission of afferent fibres [69].
Electrophysiologic and behavioural data indicate
that intrathecal administration of N/OFQ results in
analgesic action [63, 70, 71]. Despite the structural
similarities the pharmacological profile of N/OFQ is
in many cases opposite to opioids and it has addi-
tionally been demonstrated that N/OFQ results in
the suppression of opioid effects. In acute pain,
intracerebroventricular (ICV) co-administration of
N/OFQ and morphine to animals results in attenuat-
ed analgesic effects of morphine [72]. The ICV route
also reverses the analgesic effects of selective ago-
nists of MOP, KOP and DOP receptors (DAMGO,
U50,488H and DPDPE, respectively) [73, 74]. Based
on the results of many studies it may be concluded
that ICV administration of N/OFQ antagonise the
analgesic effects of morphine and other opioids,
while the NOP receptor antagonists Nphe and PheY
Table 3. A comparison of the amino acid sequence of nociceptin/orphanin FQ and dynorphin A
Nociceptin/orphanin FQ Phe-Gly-Gly-Phe -Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg- Lys -Leu-Ala- Asn-Gln
Dynorphin A Tyr-Gly-Gly-Phe -Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu- Lys -Trp-Asp- Asn-Gln
Advances in Palliative Medicine 2008, vol. 7, no. 4
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increase the dose-dependent analgesic effects of
morphine [75, 76]. In situ hybridisation studies have
shown that intrathecal morphine activates the no-
ciceptive system [76]. The increased activity of this
endogenous antiopioid system may be the reason
for the reduced effectiveness of morphine in neuro-
pathic pain and for the rapid development of toler-
ance [76]. Studies in NOP knockout mice have dem-
onstrated a slower development of morphine toler-
ance, which confirms the functional interaction be-
tween NOP and MOP receptors and points to the
important role of NOP receptors in the mechanisms
underlying the development of tolerance to mor-
phine [77].
The results of studies investigating the nocicep-
tive system enable the search of new, more effec-
tive drugs for the treatment of neuropathic pain
[78]. Many synthetic NOP receptor ligands are used
in research studies (tab. 2). In clinical practice bu-
prenorphine, a semisynthetic opioid with partial
agonistic action at MOP, KOP and DOP receptors
and complete agonistic action at NOP receptors. It
shows more pronounced analgesic properties than
morphine in neuropathic pain. Its effects on the
NOP receptor seem to play an important yet poorly
understood role. A significant topic of studies in-
vestigating the treatment of neuropathic pain is
the combined use of opioid receptor ligands and
NOP with the view to achieving optimum analgesic
effects with minimised adverse reactions.
Modulation of the effects of opioids
by glial activation inhibitors
Neuropathic pain is characterised by refractori-
ness to analgesic drugs [38, 50, 76, 79–82] and the
studies performed in the recent years have shown
that activated microglial cells play an important role
in its development [83–86]. The cells of the glia
(astroglia, oligodendrocytes, microglia) account for
70% of the central nervous system cells [87]. Recent
studies of the neuroimmune changes utilising gene
expression profiling in experimental animals on the
neuropathic pain model have proved that activa-
tion of the gene expression cascades is necessary
for the development and maintenance of neuro-
pathic pain [88, 89]. This points to the complexity
of endogenous factors that are responsible for the
initiation and regulation of neuropathic pain states.
Activated microglial cells start to produce numer-
ous proinflammatory compounds, such as cytok-
ines (IL-1a, IL-1b, TNFa, IL-6), chemokines (fractalk-
ine, MIP-1a, MIP-1b, MCP-1) and cytotoxic com-
pounds (iNOS, free oxygen and nitrogen radicals)
[85, 86, 90–92]. Further processes include the in-
duction of various surface receptors (such as TNFRI,
TNFRII, IL-1RI, CX3CR1) which accelerate immune
response [90, 93]. Recent studies have demonstrat-
ed that glial inhibitors, such as propentofylline, pen-
toxifylline, fluorocitrate and minocycline, suppress
the secretion of numerous cytokines by reducing
the activation of microglia and suppressing the de-
velopment of neuropathic pain [83, 93–96].
It seems interesting that the neuroimmune
changes in the course of neuropathic pain develop-
ment and in morphine tolerance at the molecular
level seem to be similar and concern the activation
of microglial cells [79, 84–86, 88, 95]. Chronic ad-
ministration of morphine in neuropathic pain has
been shown to additionally increase microglial pro-
liferation contributing to the development of toler-
ance [84, 95, 97]. The mechanism of morphine ef-
fects on the glia is still unknown, although it has
been established that morphine changes the mor-
phology and function of the microglia increasing,
for instance, the secretion of proinflammatory cy-
tokines, substances that suppress the effects of
morphine [85, 86, 92, 95, 97]. Many authors have
shown that cytokines, as a result of activation by
morphine, trigger changes in the activation of MAPK
and PKC kinase cascades affecting, in consequence,
intracellular signalling pathways [98]. For this rea-
son a hypothesis was proposed several years ago
according to which inhibition of glial activation could
not only attenuate the development of neuropathic
pain but also improve the effectiveness of morphine
and other drugs [85, 86, 91, 95, 99].
Song and Zhao were the first to conduct studies
on an animal model [99]. They showed that admin-
istration of the glial inhibitor fluorocitrate reduced
the development of morphine tolerance. Further
studies on animal models of neuropathic pain, in-
cluding ours, have shown that propentofylline and
pentoxifylline improve analgesic properties of mor-
phine in inflammation [100, 101]. Recently, similar
results have been obtained by giving pentoxifylline
to patients in the clinic [102] and their studies have
proved that pentoxifylline significantly reduces mor-
phine requirement in the postoperative period in
patients undergoing cholecystectomy. Reduced
blood levels of TNFa and IL-6 following surgery have
been observed in these patients. A recent clinical
study by Lu et al. [103] has confirmed that pentox-
ifylline relieves postoperative pain and very benefi-
cially improves the effectiveness of morphine as well
as causing a more rapid restoration of intestinal
function. The authors have also shown that these
effects are associated with changes in the produc-
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tion of IL-6, IL-8 and the IL-1 receptor antagonist in
the postoperative period.
Our studies in mice and rats, as well as other
studies, suggest that pentoxifylline and minocycline
both reduce the development of neuropathic pain
in mice and rats and significantly increase the effec-
tiveness of morphine on a neuropathic pain model
[83, 84, 104]. Chronic administration of morphine
in neuropathic animals results to complete devel-
opment of tolerance, while glial inhibitors delay it
[84, 97]. The results of western blot and immuno-
histochemistry indicate that minocycline and pen-
toxifylline considerably delay the development of
morphine tolerance by reducing the degree of mi-
croglial activation as a result of chronic administra-
tion of morphine [84, 97]. Minocycline, which readily
passes the blood-brain barrier, seems to be a prom-
ising substance in the treatment of neuropathic pain.
It is already being used in the clinical practice for
the treatment of Parkinson’s disease and shows neu-
roprotective properties, although there are no clini-
cal data on using it in neuropathic pain.
Studies by Ledeboer et al. [105] on animal mod-
els of neuropathic pain have shown that ibudilast
(AV411), a non-selective phosphodiesterase inhibi-
tor, suppresses the activation of glial cells, elevates
the IL-10 concentration, reduces the levels of IL-1b,
TNFa and IL-6 and increases the effectiveness of
morphine. Preclinical studies are ongoing in Austra-
lia at the moment, and their studies confirm that
ibudilast readily passes the blood-brain barrier, is
well tolerated, may be used orally, reduces glial ac-
tivation, relieves the symptoms of neuropathic pain
and increases morphine analgesia [106].
Understanding of the molecular mechanisms in
the opioid systems in chronic pain should produce
new, more effective methods of the pharmacother-
apy of pain. Pharmacological suppression of glial
activation in combination with morphine, metha-
done, fentanyl and buprenorphine may be an im-
portant aspect of pain therapy. Long-term use of
the classical opioid analgesics in patients with chron-
ic pain processes results in tolerance, and the search
of new treatment strategies based on the recogn-
ised mechanisms of pain is an important clinical
and scientific issue.
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